###begin article-title 0
Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum
###end article-title 0
###begin p 1
Expression of the transcription factor hypoxia-inducible factor 1 (HIF-1), which plays a key role in cellular adaptation to hypoxia, was investigated in normal colorectal mucosa (ten), adenomas (61), and carcinomas (23). Tissue samples were analyzed for HIF-1alpha, its upstream regulators, von Hippel-Lindau factor, AKT, and mammalian target of rapamycin (mTOR) and its downstream targets glucose transporter 1 (GLUT1), carbonic anhydrase IX, stromal-cell-derived factor 1 (SDF-1) by immunohistochemistry. In normal colorectal mucosa, HIF-1alpha was observed in almost all nuclei of surface epithelial cells, probably secondary to a gradient of oxygenation, as indicated by pimonidazole staining. The same staining pattern was present in 87% of adenomas. In carcinomas, HIF-1alpha was present predominantly around areas of necrosis (78%). Active AKT and mTOR, were present in all adenomas, carcinomas, and in normal colorectal mucosa. GLUT1 and SDF-1 were present in the normal surface epithelium of all adenoma cases, whereas in the carcinoma GLUT1 was located around necrotic regions and SDF-1 was present in all epithelial cells. In conclusion, HIF-1alpha appears to be physiologically expressed in the upper part of the colorectal mucosa. The present observations support that upregulation of HIF-1alpha and its downstream targets GLUT1 and SDF-1 in colorectal adenomas and carcinomas may be due to hypoxia, in close interaction with an active phosphatidylinositol 3-kinases-AKT-mTOR pathway.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 470 471 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 473 475 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 588 589 588 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 951 953 940 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 955 957 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1085 1087 1074 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1140 1142 1125 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 1250 1251 1235 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1253 1255 1238 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 1365 1371 1350 1356 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1371 1718 1356 1688 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="5">Schematic representation of the interaction of the analyzed proteins. The PI3K&#8211;AKT&#8211;mTOR pathway is inducing HIF-1&#945;. In addition, the absence of hypoxia prevents HIF-1&#945; from degradation mediated by VHL. When HIF-1&#945; is present, it binds to HIF-1 &#946; in the nucleus. The formed complex activates target genes, like GLUT1, SDF1, and CA IX</p>
###xml 1371 1718 1356 1688 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="5">Schematic representation of the interaction of the analyzed proteins. The PI3K&#8211;AKT&#8211;mTOR pathway is inducing HIF-1&#945;. In addition, the absence of hypoxia prevents HIF-1&#945; from degradation mediated by VHL. When HIF-1&#945; is present, it binds to HIF-1 &#946; in the nucleus. The formed complex activates target genes, like GLUT1, SDF1, and CA IX</p></caption>
###xml 1718 1718 1688 1688 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="428_2008_578_Fig1_HTML" id="MO1"/>
###xml 1365 1718 1350 1688 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="5">Schematic representation of the interaction of the analyzed proteins. The PI3K&#8211;AKT&#8211;mTOR pathway is inducing HIF-1&#945;. In addition, the absence of hypoxia prevents HIF-1&#945; from degradation mediated by VHL. When HIF-1&#945; is present, it binds to HIF-1 &#946; in the nucleus. The formed complex activates target genes, like GLUT1, SDF1, and CA IX</p></caption><graphic position="anchor" xlink:href="428_2008_578_Fig1_HTML" id="MO1"/></fig>
###xml 1240 1248 <span type="species:ncbi:9606">patients</span>
Colorectal carcinomas arise from normal epithelial cells of the colorectal mucosa through an adenoma stage. The transition from benign adenomas to malignant carcinomas, occurring in about 5% of all adenomas, is only beginning to be explored in appreciable detail. Biological changes involved in this process include important signaling pathways like the mammalian target of rapamycin (mTOR)-AKT pathway while recently also a role for hypoxia-driven signaling was shown [6, 14]. Both pathways are mediated by the transcription factor hypoxia-inducible factor 1 (HIF-1) as depicted in Fig. 1. HIF-1 is involved in cellular adaptation to hypoxia in solid tumors, including stimulation of angiogenesis and glycolysis [33]. HIF-1 consists of two subunits of which the beta-subunit is constitutively expressed, whereas HIF-1alpha is regulated in particular by the oxygen level. Under normoxia, the HIF-1alpha protein is hydroxylated by prolyl hydroxylases [15, 16], which enables the von Hippel-Lindau factor (VHL) to bind, resulting in ubiquination and rapid degradation by the proteosome [27]. HIF-1alpha is overexpressed in many solid tumors [38] and its presence has been correlated with, i.e., poor prognosis in breast and colorectal cancer patients [4, 36]. Stromal expression of hypoxia-regulated proteins is an adverse prognostic factor in colorectal carcinomas. Fig. 1Schematic representation of the interaction of the analyzed proteins. The PI3K-AKT-mTOR pathway is inducing HIF-1alpha. In addition, the absence of hypoxia prevents HIF-1alpha from degradation mediated by VHL. When HIF-1alpha is present, it binds to HIF-1 beta in the nucleus. The formed complex activates target genes, like GLUT1, SDF1, and CA IX
###end p 4
###begin p 5
Schematic representation of the interaction of the analyzed proteins. The PI3K-AKT-mTOR pathway is inducing HIF-1alpha. In addition, the absence of hypoxia prevents HIF-1alpha from degradation mediated by VHL. When HIF-1alpha is present, it binds to HIF-1 beta in the nucleus. The formed complex activates target genes, like GLUT1, SDF1, and CA IX
###end p 5
###begin p 6
###xml 238 240 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 431 432 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 594 595 590 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 597 599 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 710 711 706 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
High protein levels of HIF-1alpha are not only caused by hypoxia but can also be induced by the absence of wild-type protein 53, mutated VHL and other tumor suppressor genes, as well as by activation of oncogenes like Her2neu (c-erbB-2) [24]. In addition, growth factors play a role. However, both hypoxia and signaling-mediated HIF-1 stimulation are mediated by the phosphatidylinositol 3-kinase (PI3K)-AKT, and the mTOR pathway [8]. Interestingly, both the serine-threonine protein kinase AKT as well as mTOR have been suggested to play a role in an early stage of colorectal carcinogenesis [2, 30]. Furthermore, the presence of a non-hypoxic HIF-1 induction has also been suggested, in colorectal adenomas [9].
###end p 6
###begin p 7
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 391 392 391 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 607 608 607 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
Upon HIF-1 activation, multiple target genes become transcriptionally active, including genes involved in anaerobic glycolysis, metabolism, and angiogenesis. This includes glucose transporter 1 (GLUT1), which facilitates cellular glucose uptake [11, 26] and the angiogenesis-associated genes vascular endothelial growth factor and stromal-cell-derived factor 1 (SDF-1) also known as CXCL12 [5]. Furthermore, carbonic anhydrase IX (CA IX) which is prominently induced by hypoxia and is therefore considered to be an intrinsic hypoxia marker, which correlates with a chemical marker of hypoxia, pimonidazole [1, 17, 23, 28]. An additional function of CA IX is in the regulation of the maintenance of the physiological equilibrium in normal gastrointestinal tissue [31].
###end p 7
###begin p 8
The present study aims to analyze the role HIF-1 in normal colorectal mucosa, adenomas, and carcinomas. To this end, the presence of HIF-1alpha as well as of its downstream targets GLUT1, SDF-1, and CA IX were analyzed in normal colon tissue, colorectal adenomas, and carcinomas. To explore the possible cause of HIF-1 overexpression, i.e., hypoxia or oncogenic stimulation, both the presence of the chemical hypoxia marker pimonidazole and of the HIF-1alpha upstream regulators, VHL, AKT, and mTOR, were investigated.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
Tumor material
###end title 10
###begin p 11
###xml 376 384 <span type="species:ncbi:9606">patients</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
A total of 84 tissue samples were studied, consisting of 61 colorectal adenomas, 20 of which contained already a focus of carcinoma and are therefore referred to as progressed adenomas, in contrast to the 41 adenomas with dysplasia only, which are referred to as nonprogressed adenomas. In addition, 23 colorectal carcinomas were analyzed. These samples were obtained from 75 patients, 37 of which were female and 38 male. Mean age was 67.8 years (range 40-89). Normal mucosa samples were obtained from the resection margins of colectomy specimens from ten patients with colorectal cancer. The study was approved by the Institutional Review Board and was in accordance with Dutch medical ethical guidelines.
###end p 11
###begin title 12
Determination of hypoxic regions
###end title 12
###begin p 13
###xml 19 24 <span type="species:ncbi:10090">mouse</span>
Hypoxic regions in mouse tissues were visualized using the Hydroxyprobe-1 kit (Chemicon International, Temecula, CA, USA). These experiments were approved by the animal experimentation ethics committee, according to local and governmental regulations.
###end p 13
###begin p 14
###xml 28 41 28 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">intravenously</italic>
###xml 213 214 213 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 315 316 309 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 9 13 <span type="species:ncbi:10090">mice</span>
###xml 162 166 <span type="species:ncbi:10090">Mice</span>
Briefly, mice were injected intravenously with pimonidazole (60-mg/kg body weight), which forms adducts from reductively activated pimonidazole in hypoxic cells. Mice were killed 90 min later by asphyxiation in CO2. The Hydroxyprobe-1 monoclonal antibody was biotinylated using D-biotinyl-epsilon-aminocaproic acid N-hydroxysuccinimide ester (Boehringer Mannheim) and was used to stain pimonidazole adducts in formalin-fixed paraffin-embedded tissues according to recommendations by the manufacturer.
###end p 14
###begin title 15
Immunohistochemistry
###end title 15
###begin p 16
###xml 213 214 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 219 220 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 281 282 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 614 621 595 602 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 621 665 602 646 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17">Details of the immunohistochemical stainings</p>
###xml 621 665 602 646 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="17">Details of the immunohistochemical stainings</p></caption>
###xml 665 673 646 654 <th xmlns:xlink="http://www.w3.org/1999/xlink">Antibody</th>
###xml 673 680 654 661 <th xmlns:xlink="http://www.w3.org/1999/xlink">Species</th>
###xml 680 702 661 683 <th xmlns:xlink="http://www.w3.org/1999/xlink">Company and institutes</th>
###xml 702 710 683 691 <th xmlns:xlink="http://www.w3.org/1999/xlink">Dilution</th>
###xml 710 720 691 701 <th xmlns:xlink="http://www.w3.org/1999/xlink">Incubation</th>
###xml 720 737 701 718 <th xmlns:xlink="http://www.w3.org/1999/xlink">Antigen retrieval</th>
###xml 737 746 718 727 <th xmlns:xlink="http://www.w3.org/1999/xlink">Detection</th>
###xml 665 746 646 727 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Antibody</th><th>Species</th><th>Company and institutes</th><th>Dilution</th><th>Incubation</th><th>Antigen retrieval</th><th>Detection</th></tr>
###xml 665 746 646 727 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Antibody</th><th>Species</th><th>Company and institutes</th><th>Dilution</th><th>Incubation</th><th>Antigen retrieval</th><th>Detection</th></tr></thead>
###xml 746 756 727 733 <td xmlns:xlink="http://www.w3.org/1999/xlink">HIF-1&#945;</td>
###xml 756 761 733 738 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mouse</td>
###xml 761 774 738 751 <td xmlns:xlink="http://www.w3.org/1999/xlink">BD Pharmingen</td>
###xml 774 779 751 756 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/500</td>
###xml 779 785 756 762 <td xmlns:xlink="http://www.w3.org/1999/xlink">30&#8242; RT</td>
###xml 785 806 762 777 <td xmlns:xlink="http://www.w3.org/1999/xlink">WB TRS 97&#176;C 45&#8242;</td>
###xml 806 809 777 780 <td xmlns:xlink="http://www.w3.org/1999/xlink">CSA</td>
###xml 746 809 727 780 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HIF-1&#945;</td><td>Mouse</td><td>BD Pharmingen</td><td>1/500</td><td>30&#8242; RT</td><td>WB TRS 97&#176;C 45&#8242;</td><td>CSA</td></tr>
###xml 809 812 780 783 <td xmlns:xlink="http://www.w3.org/1999/xlink">Akt</td>
###xml 812 818 783 789 <td xmlns:xlink="http://www.w3.org/1999/xlink">Rabbit</td>
###xml 818 832 789 803 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cell Signaling</td>
###xml 832 836 803 807 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/50</td>
###xml 836 849 807 814 <td xmlns:xlink="http://www.w3.org/1999/xlink">o/n 4&#176;C</td>
###xml 849 871 814 830 <td xmlns:xlink="http://www.w3.org/1999/xlink">WB Citr 97&#176;C 10&#8242;</td>
###xml 871 874 830 833 <td xmlns:xlink="http://www.w3.org/1999/xlink">ABC</td>
###xml 809 874 780 833 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Akt</td><td>Rabbit</td><td>Cell Signaling</td><td>1/50</td><td>o/n 4&#176;C</td><td>WB Citr 97&#176;C 10&#8242;</td><td>ABC</td></tr>
###xml 874 878 833 837 <td xmlns:xlink="http://www.w3.org/1999/xlink">mTOR</td>
###xml 878 884 837 843 <td xmlns:xlink="http://www.w3.org/1999/xlink">Rabbit</td>
###xml 884 898 843 857 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cell Signaling</td>
###xml 898 902 857 861 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/50</td>
###xml 902 915 861 868 <td xmlns:xlink="http://www.w3.org/1999/xlink">o/n 4&#176;C</td>
###xml 915 937 868 884 <td xmlns:xlink="http://www.w3.org/1999/xlink">WB Citr 97&#176;C 10&#8242;</td>
###xml 937 940 884 887 <td xmlns:xlink="http://www.w3.org/1999/xlink">ABC</td>
###xml 874 940 833 887 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>mTOR</td><td>Rabbit</td><td>Cell Signaling</td><td>1/50</td><td>o/n 4&#176;C</td><td>WB Citr 97&#176;C 10&#8242;</td><td>ABC</td></tr>
###xml 940 943 887 890 <td xmlns:xlink="http://www.w3.org/1999/xlink">VHL</td>
###xml 943 948 890 895 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mouse</td>
###xml 948 961 895 908 <td xmlns:xlink="http://www.w3.org/1999/xlink">BD Pharmingen</td>
###xml 961 966 908 913 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/100</td>
###xml 966 972 913 919 <td xmlns:xlink="http://www.w3.org/1999/xlink">60&#8242; RT</td>
###xml 972 994 919 935 <td xmlns:xlink="http://www.w3.org/1999/xlink">WB Citr 97&#176;C 20&#8242;</td>
###xml 994 1005 935 946 <td xmlns:xlink="http://www.w3.org/1999/xlink">Powervision</td>
###xml 940 1005 887 946 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>VHL</td><td>Mouse</td><td>BD Pharmingen</td><td>1/100</td><td>60&#8242; RT</td><td>WB Citr 97&#176;C 20&#8242;</td><td>Powervision</td></tr>
###xml 1005 1010 946 951 <td xmlns:xlink="http://www.w3.org/1999/xlink">CA IX</td>
###xml 1010 1015 951 956 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mouse</td>
###xml 1015 1025 956 966 <td xmlns:xlink="http://www.w3.org/1999/xlink">Lab Harris</td>
###xml 1025 1029 966 970 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/50</td>
###xml 1029 1035 970 976 <td xmlns:xlink="http://www.w3.org/1999/xlink">30&#8242; RT</td>
###xml 1035 1039 976 980 <td xmlns:xlink="http://www.w3.org/1999/xlink">none</td>
###xml 1039 1048 980 989 <td xmlns:xlink="http://www.w3.org/1999/xlink">Envision+</td>
###xml 1005 1048 946 989 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>CA IX</td><td>Mouse</td><td>Lab Harris</td><td>1/50</td><td>30&#8242; RT</td><td>none</td><td>Envision+</td></tr>
###xml 1048 1054 989 995 <td xmlns:xlink="http://www.w3.org/1999/xlink">Glut-1</td>
###xml 1054 1060 995 1001 <td xmlns:xlink="http://www.w3.org/1999/xlink">Rabbit</td>
###xml 1060 1064 1001 1005 <td xmlns:xlink="http://www.w3.org/1999/xlink">DAKO</td>
###xml 1064 1069 1005 1010 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/400</td>
###xml 1069 1075 1010 1016 <td xmlns:xlink="http://www.w3.org/1999/xlink">60&#8242; RT</td>
###xml 1075 1097 1016 1032 <td xmlns:xlink="http://www.w3.org/1999/xlink">WB Citr 97&#176;C 20&#8242;</td>
###xml 1097 1100 1032 1035 <td xmlns:xlink="http://www.w3.org/1999/xlink">ABC</td>
###xml 1048 1100 989 1035 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Glut-1</td><td>Rabbit</td><td>DAKO</td><td>1/400</td><td>60&#8242; RT</td><td>WB Citr 97&#176;C 20&#8242;</td><td>ABC</td></tr>
###xml 1100 1105 1035 1040 <td xmlns:xlink="http://www.w3.org/1999/xlink">SDF-1</td>
###xml 1105 1110 1040 1045 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mouse</td>
###xml 1110 1121 1045 1056 <td xmlns:xlink="http://www.w3.org/1999/xlink">R&amp;D systems</td>
###xml 1121 1126 1056 1061 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/400</td>
###xml 1126 1139 1061 1068 <td xmlns:xlink="http://www.w3.org/1999/xlink">o/n 4&#176;C</td>
###xml 1139 1161 1068 1084 <td xmlns:xlink="http://www.w3.org/1999/xlink">WB Citr 97&#176;C 10&#8242;</td>
###xml 1161 1164 1084 1087 <td xmlns:xlink="http://www.w3.org/1999/xlink">ABC</td>
###xml 1100 1164 1035 1087 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>SDF-1</td><td>Mouse</td><td>R&amp;D systems</td><td>1/400</td><td>o/n 4&#176;C</td><td>WB Citr 97&#176;C 10&#8242;</td><td>ABC</td></tr>
###xml 1164 1178 1087 1101 <td xmlns:xlink="http://www.w3.org/1999/xlink">Hydroxyprobe-1</td>
###xml 1178 1183 1101 1106 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mouse</td>
###xml 1183 1205 1106 1128 <td xmlns:xlink="http://www.w3.org/1999/xlink">Chemicon International</td>
###xml 1205 1210 1128 1133 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/200</td>
###xml 1210 1215 1133 1138 <td xmlns:xlink="http://www.w3.org/1999/xlink">40&#8242;RT</td>
###xml 1215 1254 1138 1171 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.01% pronase in PBS 40&#176;C for 40&#8242;</td>
###xml 1254 1257 1171 1174 <td xmlns:xlink="http://www.w3.org/1999/xlink">ABC</td>
###xml 1164 1257 1087 1174 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hydroxyprobe-1</td><td>Mouse</td><td>Chemicon International</td><td>1/200</td><td>40&#8242;RT</td><td>0.01% pronase in PBS 40&#176;C for 40&#8242;</td><td>ABC</td></tr>
###xml 746 1257 727 1174 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>HIF-1&#945;</td><td>Mouse</td><td>BD Pharmingen</td><td>1/500</td><td>30&#8242; RT</td><td>WB TRS 97&#176;C 45&#8242;</td><td>CSA</td></tr><tr><td>Akt</td><td>Rabbit</td><td>Cell Signaling</td><td>1/50</td><td>o/n 4&#176;C</td><td>WB Citr 97&#176;C 10&#8242;</td><td>ABC</td></tr><tr><td>mTOR</td><td>Rabbit</td><td>Cell Signaling</td><td>1/50</td><td>o/n 4&#176;C</td><td>WB Citr 97&#176;C 10&#8242;</td><td>ABC</td></tr><tr><td>VHL</td><td>Mouse</td><td>BD Pharmingen</td><td>1/100</td><td>60&#8242; RT</td><td>WB Citr 97&#176;C 20&#8242;</td><td>Powervision</td></tr><tr><td>CA IX</td><td>Mouse</td><td>Lab Harris</td><td>1/50</td><td>30&#8242; RT</td><td>none</td><td>Envision+</td></tr><tr><td>Glut-1</td><td>Rabbit</td><td>DAKO</td><td>1/400</td><td>60&#8242; RT</td><td>WB Citr 97&#176;C 20&#8242;</td><td>ABC</td></tr><tr><td>SDF-1</td><td>Mouse</td><td>R&amp;D systems</td><td>1/400</td><td>o/n 4&#176;C</td><td>WB Citr 97&#176;C 10&#8242;</td><td>ABC</td></tr><tr><td>Hydroxyprobe-1</td><td>Mouse</td><td>Chemicon International</td><td>1/200</td><td>40&#8242;RT</td><td>0.01% pronase in PBS 40&#176;C for 40&#8242;</td><td>ABC</td></tr></tbody>
###xml 665 1257 646 1174 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Antibody</th><th>Species</th><th>Company and institutes</th><th>Dilution</th><th>Incubation</th><th>Antigen retrieval</th><th>Detection</th></tr></thead><tbody><tr><td>HIF-1&#945;</td><td>Mouse</td><td>BD Pharmingen</td><td>1/500</td><td>30&#8242; RT</td><td>WB TRS 97&#176;C 45&#8242;</td><td>CSA</td></tr><tr><td>Akt</td><td>Rabbit</td><td>Cell Signaling</td><td>1/50</td><td>o/n 4&#176;C</td><td>WB Citr 97&#176;C 10&#8242;</td><td>ABC</td></tr><tr><td>mTOR</td><td>Rabbit</td><td>Cell Signaling</td><td>1/50</td><td>o/n 4&#176;C</td><td>WB Citr 97&#176;C 10&#8242;</td><td>ABC</td></tr><tr><td>VHL</td><td>Mouse</td><td>BD Pharmingen</td><td>1/100</td><td>60&#8242; RT</td><td>WB Citr 97&#176;C 20&#8242;</td><td>Powervision</td></tr><tr><td>CA IX</td><td>Mouse</td><td>Lab Harris</td><td>1/50</td><td>30&#8242; RT</td><td>none</td><td>Envision+</td></tr><tr><td>Glut-1</td><td>Rabbit</td><td>DAKO</td><td>1/400</td><td>60&#8242; RT</td><td>WB Citr 97&#176;C 20&#8242;</td><td>ABC</td></tr><tr><td>SDF-1</td><td>Mouse</td><td>R&amp;D systems</td><td>1/400</td><td>o/n 4&#176;C</td><td>WB Citr 97&#176;C 10&#8242;</td><td>ABC</td></tr><tr><td>Hydroxyprobe-1</td><td>Mouse</td><td>Chemicon International</td><td>1/200</td><td>40&#8242;RT</td><td>0.01% pronase in PBS 40&#176;C for 40&#8242;</td><td>ABC</td></tr></tbody></table>
###xml 1257 1259 1174 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BD</italic>
###xml 1287 1290 1204 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mab</italic>
###xml 1312 1315 1229 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAb</italic>
###xml 1337 1339 1254 1256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RT</italic>
###xml 1358 1360 1275 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WB</italic>
###xml 1373 1376 1290 1293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRS</italic>
###xml 1411 1415 1328 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Citr</italic>
###xml 1445 1448 1362 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSA</italic>
###xml 1495 1498 1412 1415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABC</italic>
###xml 1539 1550 1456 1467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Powervision</italic>
###xml 1257 1579 1174 1496 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18"><italic>BD</italic> Transduction laboratories, <italic>Mab</italic> monoclonal antibody, <italic>PAb</italic> polyclonal antibody, <italic>RT</italic> room temperature, <italic>WB</italic> water bath, <italic>TRS</italic> target retrieval solution (DAKO), <italic>Citr</italic> citrate buffer 10&#160;mM pH 6.0, <italic>CSA</italic> catalyzed signal amplification system (DAKO), <italic>ABC</italic> avidin&#8211;biotinylated peroxidase complex, <italic>Powervision</italic> from immunologic R&amp;D systems</p>
###xml 1257 1579 1174 1496 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="18"><italic>BD</italic> Transduction laboratories, <italic>Mab</italic> monoclonal antibody, <italic>PAb</italic> polyclonal antibody, <italic>RT</italic> room temperature, <italic>WB</italic> water bath, <italic>TRS</italic> target retrieval solution (DAKO), <italic>Citr</italic> citrate buffer 10&#160;mM pH 6.0, <italic>CSA</italic> catalyzed signal amplification system (DAKO), <italic>ABC</italic> avidin&#8211;biotinylated peroxidase complex, <italic>Powervision</italic> from immunologic R&amp;D systems</p></table-wrap-foot>
###xml 614 1579 595 1496 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="17">Details of the immunohistochemical stainings</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Antibody</th><th>Species</th><th>Company and institutes</th><th>Dilution</th><th>Incubation</th><th>Antigen retrieval</th><th>Detection</th></tr></thead><tbody><tr><td>HIF-1&#945;</td><td>Mouse</td><td>BD Pharmingen</td><td>1/500</td><td>30&#8242; RT</td><td>WB TRS 97&#176;C 45&#8242;</td><td>CSA</td></tr><tr><td>Akt</td><td>Rabbit</td><td>Cell Signaling</td><td>1/50</td><td>o/n 4&#176;C</td><td>WB Citr 97&#176;C 10&#8242;</td><td>ABC</td></tr><tr><td>mTOR</td><td>Rabbit</td><td>Cell Signaling</td><td>1/50</td><td>o/n 4&#176;C</td><td>WB Citr 97&#176;C 10&#8242;</td><td>ABC</td></tr><tr><td>VHL</td><td>Mouse</td><td>BD Pharmingen</td><td>1/100</td><td>60&#8242; RT</td><td>WB Citr 97&#176;C 20&#8242;</td><td>Powervision</td></tr><tr><td>CA IX</td><td>Mouse</td><td>Lab Harris</td><td>1/50</td><td>30&#8242; RT</td><td>none</td><td>Envision+</td></tr><tr><td>Glut-1</td><td>Rabbit</td><td>DAKO</td><td>1/400</td><td>60&#8242; RT</td><td>WB Citr 97&#176;C 20&#8242;</td><td>ABC</td></tr><tr><td>SDF-1</td><td>Mouse</td><td>R&amp;D systems</td><td>1/400</td><td>o/n 4&#176;C</td><td>WB Citr 97&#176;C 10&#8242;</td><td>ABC</td></tr><tr><td>Hydroxyprobe-1</td><td>Mouse</td><td>Chemicon International</td><td>1/200</td><td>40&#8242;RT</td><td>0.01% pronase in PBS 40&#176;C for 40&#8242;</td><td>ABC</td></tr></tbody></table><table-wrap-foot><p textid="18"><italic>BD</italic> Transduction laboratories, <italic>Mab</italic> monoclonal antibody, <italic>PAb</italic> polyclonal antibody, <italic>RT</italic> room temperature, <italic>WB</italic> water bath, <italic>TRS</italic> target retrieval solution (DAKO), <italic>Citr</italic> citrate buffer 10&#160;mM pH 6.0, <italic>CSA</italic> catalyzed signal amplification system (DAKO), <italic>ABC</italic> avidin&#8211;biotinylated peroxidase complex, <italic>Powervision</italic> from immunologic R&amp;D systems</p></table-wrap-foot></table-wrap>
###xml 1579 1586 1496 1503 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 1586 1803 1503 1716 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="19">Number (and percentages) of HIF-1&#945;, P-AKT, P-mTOR, VHL, CA IX, GLUT1, and SDF-1 expression in nonprogressed and progressed colorectal adenomas and adenocarcinomas in the respective categories of staining intensity</p>
###xml 1586 1803 1503 1716 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="19">Number (and percentages) of HIF-1&#945;, P-AKT, P-mTOR, VHL, CA IX, GLUT1, and SDF-1 expression in nonprogressed and progressed colorectal adenomas and adenocarcinomas in the respective categories of staining intensity</p></caption>
###xml 1803 1804 1716 1717 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">&#160;</th>
###xml 1827 1828 1740 1741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1804 1833 1717 1746 <th xmlns:xlink="http://www.w3.org/1999/xlink">Nonprogressed Adenoma, <italic>n</italic>&#8201;=&#8201;41</th>
###xml 1853 1854 1766 1767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1833 1859 1746 1772 <th xmlns:xlink="http://www.w3.org/1999/xlink">Progressed adenoma, <italic>n</italic>&#8201;=&#8201;20</th>
###xml 1875 1876 1788 1789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1859 1881 1772 1794 <th xmlns:xlink="http://www.w3.org/1999/xlink">Adenocarcinoma, <italic>n</italic>&#8201;=&#8201;23</th>
###xml 1902 1903 1815 1816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1881 1909 1794 1822 <th xmlns:xlink="http://www.w3.org/1999/xlink">Kruskal&#8211;Wallis test, <italic>P</italic>-value</th>
###xml 1803 1909 1716 1822 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="2">&#160;</th><th>Nonprogressed Adenoma, <italic>n</italic>&#8201;=&#8201;41</th><th>Progressed adenoma, <italic>n</italic>&#8201;=&#8201;20</th><th>Adenocarcinoma, <italic>n</italic>&#8201;=&#8201;23</th><th>Kruskal&#8211;Wallis test, <italic>P</italic>-value</th></tr>
###xml 1803 1909 1716 1822 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="2">&#160;</th><th>Nonprogressed Adenoma, <italic>n</italic>&#8201;=&#8201;41</th><th>Progressed adenoma, <italic>n</italic>&#8201;=&#8201;20</th><th>Adenocarcinoma, <italic>n</italic>&#8201;=&#8201;23</th><th>Kruskal&#8211;Wallis test, <italic>P</italic>-value</th></tr></thead>
###xml 1909 1914 1822 1827 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4">HIF-1</td>
###xml 1914 1917 1827 1830 <td xmlns:xlink="http://www.w3.org/1999/xlink">Neg</td>
###xml 1917 1923 1830 1836 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">6 (15)</td>
###xml 1923 1929 1836 1842 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2 (10)</td>
###xml 1929 1935 1842 1848 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">5 (22)</td>
###xml 1935 1938 1848 1851 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4">0.8</td>
###xml 1909 1938 1822 1851 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="4">HIF-1</td><td>Neg</td><td char="(" align="char">6 (15)</td><td char="(" align="char">2 (10)</td><td char="(" align="char">5 (22)</td><td rowspan="4">0.8</td></tr>
###xml 1938 1939 1851 1852 <td xmlns:xlink="http://www.w3.org/1999/xlink">+</td>
###xml 1939 1944 1852 1857 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 1944 1950 1857 1863 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2 (10)</td>
###xml 1950 1955 1863 1868 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1 (4)</td>
###xml 1938 1955 1851 1868 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>+</td><td char="(" align="char">0 (0)</td><td char="(" align="char">2 (10)</td><td char="(" align="char">1 (4)</td></tr>
###xml 1955 1957 1868 1870 <td xmlns:xlink="http://www.w3.org/1999/xlink">++</td>
###xml 1957 1963 1870 1876 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">7 (17)</td>
###xml 1963 1969 1876 1882 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">3 (15)</td>
###xml 1969 1975 1882 1888 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">3 (13)</td>
###xml 1955 1975 1868 1888 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>++</td><td char="(" align="char">7 (17)</td><td char="(" align="char">3 (15)</td><td char="(" align="char">3 (13)</td></tr>
###xml 1975 1978 1888 1891 <td xmlns:xlink="http://www.w3.org/1999/xlink">+++</td>
###xml 1978 1985 1891 1898 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">28 (68)</td>
###xml 1985 1992 1898 1905 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">13 (65)</td>
###xml 1992 1999 1905 1912 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">14 (61)</td>
###xml 1975 1999 1888 1912 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>+++</td><td char="(" align="char">28 (68)</td><td char="(" align="char">13 (65)</td><td char="(" align="char">14 (61)</td></tr>
###xml 1999 2002 1912 1915 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4">AKT</td>
###xml 2002 2005 1915 1918 <td xmlns:xlink="http://www.w3.org/1999/xlink">Neg</td>
###xml 2005 2010 1918 1923 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2010 2015 1923 1928 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2015 2020 1928 1933 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2020 2023 1933 1936 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4">0.1</td>
###xml 1999 2023 1912 1936 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="4">AKT</td><td>Neg</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td><td rowspan="4">0.1</td></tr>
###xml 2023 2024 1936 1937 <td xmlns:xlink="http://www.w3.org/1999/xlink">+</td>
###xml 2024 2031 1937 1944 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">12 (29)</td>
###xml 2031 2037 1944 1950 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">7 (35)</td>
###xml 2037 2042 1950 1955 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2023 2042 1936 1955 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>+</td><td char="(" align="char">12 (29)</td><td char="(" align="char">7 (35)</td><td char="(" align="char">0 (0)</td></tr>
###xml 2042 2044 1955 1957 <td xmlns:xlink="http://www.w3.org/1999/xlink">++</td>
###xml 2044 2051 1957 1964 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">11 (27)</td>
###xml 2051 2057 1964 1970 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">5 (25)</td>
###xml 2057 2064 1970 1977 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">10 (43)</td>
###xml 2042 2064 1955 1977 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>++</td><td char="(" align="char">11 (27)</td><td char="(" align="char">5 (25)</td><td char="(" align="char">10 (43)</td></tr>
###xml 2064 2067 1977 1980 <td xmlns:xlink="http://www.w3.org/1999/xlink">+++</td>
###xml 2067 2074 1980 1987 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">18 (78)</td>
###xml 2074 2080 1987 1993 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">8 (40)</td>
###xml 2080 2087 1993 2000 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">13 (57)</td>
###xml 2064 2087 1977 2000 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>+++</td><td char="(" align="char">18 (78)</td><td char="(" align="char">8 (40)</td><td char="(" align="char">13 (57)</td></tr>
###xml 2087 2091 2000 2004 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4">mTOR</td>
###xml 2091 2094 2004 2007 <td xmlns:xlink="http://www.w3.org/1999/xlink">Neg</td>
###xml 2094 2099 2007 2012 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2 (5)</td>
###xml 2104 2105 2017 2018 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2099 2105 2012 2018 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)<sup>a</sup></td>
###xml 2105 2110 2018 2023 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2110 2113 2023 2026 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4">0.4</td>
###xml 2087 2113 2000 2026 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="4">mTOR</td><td>Neg</td><td char="(" align="char">2 (5)</td><td char="(" align="char">0 (0)<sup>a</sup></td><td char="(" align="char">0 (0)</td><td rowspan="4">0.4</td></tr>
###xml 2113 2114 2026 2027 <td xmlns:xlink="http://www.w3.org/1999/xlink">+</td>
###xml 2114 2119 2027 2032 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2 (5)</td>
###xml 2119 2125 2032 2038 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">3 (16)</td>
###xml 2125 2130 2038 2043 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2113 2130 2026 2043 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>+</td><td char="(" align="char">2 (5)</td><td char="(" align="char">3 (16)</td><td char="(" align="char">0 (0)</td></tr>
###xml 2130 2132 2043 2045 <td xmlns:xlink="http://www.w3.org/1999/xlink">++</td>
###xml 2132 2139 2045 2052 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">12 (29)</td>
###xml 2139 2145 2052 2058 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">6 (32)</td>
###xml 2145 2151 2058 2064 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">7 (30)</td>
###xml 2130 2151 2043 2064 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>++</td><td char="(" align="char">12 (29)</td><td char="(" align="char">6 (32)</td><td char="(" align="char">7 (30)</td></tr>
###xml 2151 2154 2064 2067 <td xmlns:xlink="http://www.w3.org/1999/xlink">+++</td>
###xml 2154 2161 2067 2074 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">25 (61)</td>
###xml 2161 2168 2074 2081 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">10 (53)</td>
###xml 2168 2175 2081 2088 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">16 (70)</td>
###xml 2151 2175 2064 2088 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>+++</td><td char="(" align="char">25 (61)</td><td char="(" align="char">10 (53)</td><td char="(" align="char">16 (70)</td></tr>
###xml 2175 2178 2088 2091 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4">VHL</td>
###xml 2178 2181 2091 2094 <td xmlns:xlink="http://www.w3.org/1999/xlink">Neg</td>
###xml 2186 2187 2099 2100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2181 2187 2094 2100 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)<sup>a</sup></td>
###xml 2187 2192 2100 2105 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1 (5)</td>
###xml 2192 2197 2105 2110 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2197 2200 2110 2113 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4">0.9</td>
###xml 2175 2200 2088 2113 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="4">VHL</td><td>Neg</td><td char="(" align="char">0 (0)<sup>a</sup></td><td char="(" align="char">1 (5)</td><td char="(" align="char">0 (0)</td><td rowspan="4">0.9</td></tr>
###xml 2200 2201 2113 2114 <td xmlns:xlink="http://www.w3.org/1999/xlink">+</td>
###xml 2201 2207 2114 2120 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">7 (18)</td>
###xml 2207 2212 2120 2125 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2212 2217 2125 2130 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1 (4)</td>
###xml 2200 2217 2113 2130 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>+</td><td char="(" align="char">7 (18)</td><td char="(" align="char">0 (0)</td><td char="(" align="char">1 (4)</td></tr>
###xml 2217 2219 2130 2132 <td xmlns:xlink="http://www.w3.org/1999/xlink">++</td>
###xml 2219 2226 2132 2139 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">12 (30)</td>
###xml 2226 2233 2139 2146 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">11 (55)</td>
###xml 2233 2240 2146 2153 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">11 (48)</td>
###xml 2217 2240 2130 2153 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>++</td><td char="(" align="char">12 (30)</td><td char="(" align="char">11 (55)</td><td char="(" align="char">11 (48)</td></tr>
###xml 2240 2243 2153 2156 <td xmlns:xlink="http://www.w3.org/1999/xlink">+++</td>
###xml 2243 2250 2156 2163 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">21 (53)</td>
###xml 2250 2256 2163 2169 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">8 (40)</td>
###xml 2256 2263 2169 2176 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">11 (48)</td>
###xml 2240 2263 2153 2176 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>+++</td><td char="(" align="char">21 (53)</td><td char="(" align="char">8 (40)</td><td char="(" align="char">11 (48)</td></tr>
###xml 2263 2268 2176 2181 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4">CA IX</td>
###xml 2268 2271 2181 2184 <td xmlns:xlink="http://www.w3.org/1999/xlink">Neg</td>
###xml 2271 2278 2184 2191 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">10 (24)</td>
###xml 2278 2284 2191 2197 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">4 (20)</td>
###xml 2284 2289 2197 2202 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1 (4)</td>
###xml 2289 2292 2202 2205 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4">0.3</td>
###xml 2263 2292 2176 2205 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="4">CA IX</td><td>Neg</td><td char="(" align="char">10 (24)</td><td char="(" align="char">4 (20)</td><td char="(" align="char">1 (4)</td><td rowspan="4">0.3</td></tr>
###xml 2292 2293 2205 2206 <td xmlns:xlink="http://www.w3.org/1999/xlink">+</td>
###xml 2293 2298 2206 2211 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2298 2303 2211 2216 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2303 2308 2216 2221 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2292 2308 2205 2221 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>+</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td></tr>
###xml 2308 2310 2221 2223 <td xmlns:xlink="http://www.w3.org/1999/xlink">++</td>
###xml 2310 2315 2223 2228 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1 (2)</td>
###xml 2315 2321 2228 2234 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2 (10)</td>
###xml 2321 2326 2234 2239 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2 (9)</td>
###xml 2308 2326 2221 2239 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>++</td><td char="(" align="char">1 (2)</td><td char="(" align="char">2 (10)</td><td char="(" align="char">2 (9)</td></tr>
###xml 2326 2329 2239 2242 <td xmlns:xlink="http://www.w3.org/1999/xlink">+++</td>
###xml 2329 2336 2242 2249 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">30 (73)</td>
###xml 2336 2343 2249 2256 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">14 (70)</td>
###xml 2343 2350 2256 2263 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">20 (87)</td>
###xml 2326 2350 2239 2263 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>+++</td><td char="(" align="char">30 (73)</td><td char="(" align="char">14 (70)</td><td char="(" align="char">20 (87)</td></tr>
###xml 2350 2355 2263 2268 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4">GLUT1</td>
###xml 2355 2358 2268 2271 <td xmlns:xlink="http://www.w3.org/1999/xlink">Neg</td>
###xml 2358 2363 2271 2276 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2363 2368 2276 2281 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1 (5)</td>
###xml 2368 2373 2281 2286 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2373 2377 2286 2290 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4">0.02</td>
###xml 2350 2377 2263 2290 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="4">GLUT1</td><td>Neg</td><td char="(" align="char">0 (0)</td><td char="(" align="char">1 (5)</td><td char="(" align="char">0 (0)</td><td rowspan="4">0.02</td></tr>
###xml 2377 2378 2290 2291 <td xmlns:xlink="http://www.w3.org/1999/xlink">+</td>
###xml 2378 2384 2291 2297 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">8 (20)</td>
###xml 2384 2390 2297 2303 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">6 (30)</td>
###xml 2390 2395 2303 2308 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2377 2395 2290 2308 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>+</td><td char="(" align="char">8 (20)</td><td char="(" align="char">6 (30)</td><td char="(" align="char">0 (0)</td></tr>
###xml 2395 2397 2308 2310 <td xmlns:xlink="http://www.w3.org/1999/xlink">++</td>
###xml 2397 2404 2310 2317 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">15 (37)</td>
###xml 2404 2410 2317 2323 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">4 (20)</td>
###xml 2410 2416 2323 2329 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">6 (26)</td>
###xml 2395 2416 2308 2329 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>++</td><td char="(" align="char">15 (37)</td><td char="(" align="char">4 (20)</td><td char="(" align="char">6 (26)</td></tr>
###xml 2416 2419 2329 2332 <td xmlns:xlink="http://www.w3.org/1999/xlink">+++</td>
###xml 2419 2426 2332 2339 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">18 (44)</td>
###xml 2426 2432 2339 2345 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">9 (45)</td>
###xml 2432 2439 2345 2352 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">17 (74)</td>
###xml 2416 2439 2329 2352 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>+++</td><td char="(" align="char">18 (44)</td><td char="(" align="char">9 (45)</td><td char="(" align="char">17 (74)</td></tr>
###xml 2439 2443 2352 2356 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4">SDF1</td>
###xml 2443 2446 2356 2359 <td xmlns:xlink="http://www.w3.org/1999/xlink">Neg</td>
###xml 2452 2453 2365 2366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2446 2453 2359 2366 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">8 (20)<sup>a</sup></td>
###xml 2459 2460 2372 2373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2453 2460 2366 2373 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">7 (37)<sup>a</sup></td>
###xml 2460 2465 2373 2378 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2465 2471 2378 2384 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4">&lt;0.005</td>
###xml 2439 2471 2352 2384 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="4">SDF1</td><td>Neg</td><td char="(" align="char">8 (20)<sup>a</sup></td><td char="(" align="char">7 (37)<sup>a</sup></td><td char="(" align="char">0 (0)</td><td rowspan="4">&lt;0.005</td></tr>
###xml 2471 2472 2384 2385 <td xmlns:xlink="http://www.w3.org/1999/xlink">+</td>
###xml 2472 2478 2385 2391 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">4 (10)</td>
###xml 2478 2484 2391 2397 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">4 (21)</td>
###xml 2484 2489 2397 2402 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">0 (0)</td>
###xml 2471 2489 2384 2402 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>+</td><td char="(" align="char">4 (10)</td><td char="(" align="char">4 (21)</td><td char="(" align="char">0 (0)</td></tr>
###xml 2489 2491 2402 2404 <td xmlns:xlink="http://www.w3.org/1999/xlink">++</td>
###xml 2491 2498 2404 2411 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">13 (33)</td>
###xml 2498 2504 2411 2417 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2 (11)</td>
###xml 2504 2510 2417 2423 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">5 (22)</td>
###xml 2489 2510 2402 2423 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>++</td><td char="(" align="char">13 (33)</td><td char="(" align="char">2 (11)</td><td char="(" align="char">5 (22)</td></tr>
###xml 2510 2513 2423 2426 <td xmlns:xlink="http://www.w3.org/1999/xlink">+++</td>
###xml 2513 2520 2426 2433 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">15 (38)</td>
###xml 2520 2526 2433 2439 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">6 (32)</td>
###xml 2526 2533 2439 2446 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">18 (78)</td>
###xml 2510 2533 2423 2446 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>+++</td><td char="(" align="char">15 (38)</td><td char="(" align="char">6 (32)</td><td char="(" align="char">18 (78)</td></tr>
###xml 1909 2533 1822 2446 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td rowspan="4">HIF-1</td><td>Neg</td><td char="(" align="char">6 (15)</td><td char="(" align="char">2 (10)</td><td char="(" align="char">5 (22)</td><td rowspan="4">0.8</td></tr><tr><td>+</td><td char="(" align="char">0 (0)</td><td char="(" align="char">2 (10)</td><td char="(" align="char">1 (4)</td></tr><tr><td>++</td><td char="(" align="char">7 (17)</td><td char="(" align="char">3 (15)</td><td char="(" align="char">3 (13)</td></tr><tr><td>+++</td><td char="(" align="char">28 (68)</td><td char="(" align="char">13 (65)</td><td char="(" align="char">14 (61)</td></tr><tr><td rowspan="4">AKT</td><td>Neg</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td><td rowspan="4">0.1</td></tr><tr><td>+</td><td char="(" align="char">12 (29)</td><td char="(" align="char">7 (35)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">11 (27)</td><td char="(" align="char">5 (25)</td><td char="(" align="char">10 (43)</td></tr><tr><td>+++</td><td char="(" align="char">18 (78)</td><td char="(" align="char">8 (40)</td><td char="(" align="char">13 (57)</td></tr><tr><td rowspan="4">mTOR</td><td>Neg</td><td char="(" align="char">2 (5)</td><td char="(" align="char">0 (0)<sup>a</sup></td><td char="(" align="char">0 (0)</td><td rowspan="4">0.4</td></tr><tr><td>+</td><td char="(" align="char">2 (5)</td><td char="(" align="char">3 (16)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">12 (29)</td><td char="(" align="char">6 (32)</td><td char="(" align="char">7 (30)</td></tr><tr><td>+++</td><td char="(" align="char">25 (61)</td><td char="(" align="char">10 (53)</td><td char="(" align="char">16 (70)</td></tr><tr><td rowspan="4">VHL</td><td>Neg</td><td char="(" align="char">0 (0)<sup>a</sup></td><td char="(" align="char">1 (5)</td><td char="(" align="char">0 (0)</td><td rowspan="4">0.9</td></tr><tr><td>+</td><td char="(" align="char">7 (18)</td><td char="(" align="char">0 (0)</td><td char="(" align="char">1 (4)</td></tr><tr><td>++</td><td char="(" align="char">12 (30)</td><td char="(" align="char">11 (55)</td><td char="(" align="char">11 (48)</td></tr><tr><td>+++</td><td char="(" align="char">21 (53)</td><td char="(" align="char">8 (40)</td><td char="(" align="char">11 (48)</td></tr><tr><td rowspan="4">CA IX</td><td>Neg</td><td char="(" align="char">10 (24)</td><td char="(" align="char">4 (20)</td><td char="(" align="char">1 (4)</td><td rowspan="4">0.3</td></tr><tr><td>+</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">1 (2)</td><td char="(" align="char">2 (10)</td><td char="(" align="char">2 (9)</td></tr><tr><td>+++</td><td char="(" align="char">30 (73)</td><td char="(" align="char">14 (70)</td><td char="(" align="char">20 (87)</td></tr><tr><td rowspan="4">GLUT1</td><td>Neg</td><td char="(" align="char">0 (0)</td><td char="(" align="char">1 (5)</td><td char="(" align="char">0 (0)</td><td rowspan="4">0.02</td></tr><tr><td>+</td><td char="(" align="char">8 (20)</td><td char="(" align="char">6 (30)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">15 (37)</td><td char="(" align="char">4 (20)</td><td char="(" align="char">6 (26)</td></tr><tr><td>+++</td><td char="(" align="char">18 (44)</td><td char="(" align="char">9 (45)</td><td char="(" align="char">17 (74)</td></tr><tr><td rowspan="4">SDF1</td><td>Neg</td><td char="(" align="char">8 (20)<sup>a</sup></td><td char="(" align="char">7 (37)<sup>a</sup></td><td char="(" align="char">0 (0)</td><td rowspan="4">&lt;0.005</td></tr><tr><td>+</td><td char="(" align="char">4 (10)</td><td char="(" align="char">4 (21)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">13 (33)</td><td char="(" align="char">2 (11)</td><td char="(" align="char">5 (22)</td></tr><tr><td>+++</td><td char="(" align="char">15 (38)</td><td char="(" align="char">6 (32)</td><td char="(" align="char">18 (78)</td></tr></tbody>
###xml 1803 2533 1716 2446 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="2">&#160;</th><th>Nonprogressed Adenoma, <italic>n</italic>&#8201;=&#8201;41</th><th>Progressed adenoma, <italic>n</italic>&#8201;=&#8201;20</th><th>Adenocarcinoma, <italic>n</italic>&#8201;=&#8201;23</th><th>Kruskal&#8211;Wallis test, <italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="4">HIF-1</td><td>Neg</td><td char="(" align="char">6 (15)</td><td char="(" align="char">2 (10)</td><td char="(" align="char">5 (22)</td><td rowspan="4">0.8</td></tr><tr><td>+</td><td char="(" align="char">0 (0)</td><td char="(" align="char">2 (10)</td><td char="(" align="char">1 (4)</td></tr><tr><td>++</td><td char="(" align="char">7 (17)</td><td char="(" align="char">3 (15)</td><td char="(" align="char">3 (13)</td></tr><tr><td>+++</td><td char="(" align="char">28 (68)</td><td char="(" align="char">13 (65)</td><td char="(" align="char">14 (61)</td></tr><tr><td rowspan="4">AKT</td><td>Neg</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td><td rowspan="4">0.1</td></tr><tr><td>+</td><td char="(" align="char">12 (29)</td><td char="(" align="char">7 (35)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">11 (27)</td><td char="(" align="char">5 (25)</td><td char="(" align="char">10 (43)</td></tr><tr><td>+++</td><td char="(" align="char">18 (78)</td><td char="(" align="char">8 (40)</td><td char="(" align="char">13 (57)</td></tr><tr><td rowspan="4">mTOR</td><td>Neg</td><td char="(" align="char">2 (5)</td><td char="(" align="char">0 (0)<sup>a</sup></td><td char="(" align="char">0 (0)</td><td rowspan="4">0.4</td></tr><tr><td>+</td><td char="(" align="char">2 (5)</td><td char="(" align="char">3 (16)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">12 (29)</td><td char="(" align="char">6 (32)</td><td char="(" align="char">7 (30)</td></tr><tr><td>+++</td><td char="(" align="char">25 (61)</td><td char="(" align="char">10 (53)</td><td char="(" align="char">16 (70)</td></tr><tr><td rowspan="4">VHL</td><td>Neg</td><td char="(" align="char">0 (0)<sup>a</sup></td><td char="(" align="char">1 (5)</td><td char="(" align="char">0 (0)</td><td rowspan="4">0.9</td></tr><tr><td>+</td><td char="(" align="char">7 (18)</td><td char="(" align="char">0 (0)</td><td char="(" align="char">1 (4)</td></tr><tr><td>++</td><td char="(" align="char">12 (30)</td><td char="(" align="char">11 (55)</td><td char="(" align="char">11 (48)</td></tr><tr><td>+++</td><td char="(" align="char">21 (53)</td><td char="(" align="char">8 (40)</td><td char="(" align="char">11 (48)</td></tr><tr><td rowspan="4">CA IX</td><td>Neg</td><td char="(" align="char">10 (24)</td><td char="(" align="char">4 (20)</td><td char="(" align="char">1 (4)</td><td rowspan="4">0.3</td></tr><tr><td>+</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">1 (2)</td><td char="(" align="char">2 (10)</td><td char="(" align="char">2 (9)</td></tr><tr><td>+++</td><td char="(" align="char">30 (73)</td><td char="(" align="char">14 (70)</td><td char="(" align="char">20 (87)</td></tr><tr><td rowspan="4">GLUT1</td><td>Neg</td><td char="(" align="char">0 (0)</td><td char="(" align="char">1 (5)</td><td char="(" align="char">0 (0)</td><td rowspan="4">0.02</td></tr><tr><td>+</td><td char="(" align="char">8 (20)</td><td char="(" align="char">6 (30)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">15 (37)</td><td char="(" align="char">4 (20)</td><td char="(" align="char">6 (26)</td></tr><tr><td>+++</td><td char="(" align="char">18 (44)</td><td char="(" align="char">9 (45)</td><td char="(" align="char">17 (74)</td></tr><tr><td rowspan="4">SDF1</td><td>Neg</td><td char="(" align="char">8 (20)<sup>a</sup></td><td char="(" align="char">7 (37)<sup>a</sup></td><td char="(" align="char">0 (0)</td><td rowspan="4">&lt;0.005</td></tr><tr><td>+</td><td char="(" align="char">4 (10)</td><td char="(" align="char">4 (21)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">13 (33)</td><td char="(" align="char">2 (11)</td><td char="(" align="char">5 (22)</td></tr><tr><td>+++</td><td char="(" align="char">15 (38)</td><td char="(" align="char">6 (32)</td><td char="(" align="char">18 (78)</td></tr></tbody></table>
###xml 2533 2534 2446 2447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2533 2553 2446 2466 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="20"><sup>a</sup>One case not tested</p>
###xml 2533 2553 2446 2466 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="20"><sup>a</sup>One case not tested</p></table-wrap-foot>
###xml 1579 2553 1496 2466 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="19">Number (and percentages) of HIF-1&#945;, P-AKT, P-mTOR, VHL, CA IX, GLUT1, and SDF-1 expression in nonprogressed and progressed colorectal adenomas and adenocarcinomas in the respective categories of staining intensity</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">&#160;</th><th>Nonprogressed Adenoma, <italic>n</italic>&#8201;=&#8201;41</th><th>Progressed adenoma, <italic>n</italic>&#8201;=&#8201;20</th><th>Adenocarcinoma, <italic>n</italic>&#8201;=&#8201;23</th><th>Kruskal&#8211;Wallis test, <italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="4">HIF-1</td><td>Neg</td><td char="(" align="char">6 (15)</td><td char="(" align="char">2 (10)</td><td char="(" align="char">5 (22)</td><td rowspan="4">0.8</td></tr><tr><td>+</td><td char="(" align="char">0 (0)</td><td char="(" align="char">2 (10)</td><td char="(" align="char">1 (4)</td></tr><tr><td>++</td><td char="(" align="char">7 (17)</td><td char="(" align="char">3 (15)</td><td char="(" align="char">3 (13)</td></tr><tr><td>+++</td><td char="(" align="char">28 (68)</td><td char="(" align="char">13 (65)</td><td char="(" align="char">14 (61)</td></tr><tr><td rowspan="4">AKT</td><td>Neg</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td><td rowspan="4">0.1</td></tr><tr><td>+</td><td char="(" align="char">12 (29)</td><td char="(" align="char">7 (35)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">11 (27)</td><td char="(" align="char">5 (25)</td><td char="(" align="char">10 (43)</td></tr><tr><td>+++</td><td char="(" align="char">18 (78)</td><td char="(" align="char">8 (40)</td><td char="(" align="char">13 (57)</td></tr><tr><td rowspan="4">mTOR</td><td>Neg</td><td char="(" align="char">2 (5)</td><td char="(" align="char">0 (0)<sup>a</sup></td><td char="(" align="char">0 (0)</td><td rowspan="4">0.4</td></tr><tr><td>+</td><td char="(" align="char">2 (5)</td><td char="(" align="char">3 (16)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">12 (29)</td><td char="(" align="char">6 (32)</td><td char="(" align="char">7 (30)</td></tr><tr><td>+++</td><td char="(" align="char">25 (61)</td><td char="(" align="char">10 (53)</td><td char="(" align="char">16 (70)</td></tr><tr><td rowspan="4">VHL</td><td>Neg</td><td char="(" align="char">0 (0)<sup>a</sup></td><td char="(" align="char">1 (5)</td><td char="(" align="char">0 (0)</td><td rowspan="4">0.9</td></tr><tr><td>+</td><td char="(" align="char">7 (18)</td><td char="(" align="char">0 (0)</td><td char="(" align="char">1 (4)</td></tr><tr><td>++</td><td char="(" align="char">12 (30)</td><td char="(" align="char">11 (55)</td><td char="(" align="char">11 (48)</td></tr><tr><td>+++</td><td char="(" align="char">21 (53)</td><td char="(" align="char">8 (40)</td><td char="(" align="char">11 (48)</td></tr><tr><td rowspan="4">CA IX</td><td>Neg</td><td char="(" align="char">10 (24)</td><td char="(" align="char">4 (20)</td><td char="(" align="char">1 (4)</td><td rowspan="4">0.3</td></tr><tr><td>+</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">1 (2)</td><td char="(" align="char">2 (10)</td><td char="(" align="char">2 (9)</td></tr><tr><td>+++</td><td char="(" align="char">30 (73)</td><td char="(" align="char">14 (70)</td><td char="(" align="char">20 (87)</td></tr><tr><td rowspan="4">GLUT1</td><td>Neg</td><td char="(" align="char">0 (0)</td><td char="(" align="char">1 (5)</td><td char="(" align="char">0 (0)</td><td rowspan="4">0.02</td></tr><tr><td>+</td><td char="(" align="char">8 (20)</td><td char="(" align="char">6 (30)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">15 (37)</td><td char="(" align="char">4 (20)</td><td char="(" align="char">6 (26)</td></tr><tr><td>+++</td><td char="(" align="char">18 (44)</td><td char="(" align="char">9 (45)</td><td char="(" align="char">17 (74)</td></tr><tr><td rowspan="4">SDF1</td><td>Neg</td><td char="(" align="char">8 (20)<sup>a</sup></td><td char="(" align="char">7 (37)<sup>a</sup></td><td char="(" align="char">0 (0)</td><td rowspan="4">&lt;0.005</td></tr><tr><td>+</td><td char="(" align="char">4 (10)</td><td char="(" align="char">4 (21)</td><td char="(" align="char">0 (0)</td></tr><tr><td>++</td><td char="(" align="char">13 (33)</td><td char="(" align="char">2 (11)</td><td char="(" align="char">5 (22)</td></tr><tr><td>+++</td><td char="(" align="char">15 (38)</td><td char="(" align="char">6 (32)</td><td char="(" align="char">18 (78)</td></tr></tbody></table><table-wrap-foot><p textid="20"><sup>a</sup>One case not tested</p></table-wrap-foot></table-wrap>
Immunohistochemistry was performed on 4-mum-thick full-block consecutive sections. Slides were deparaffinized, followed by rehydration, and subsequently staining in batches with the antibodies described in Tables 1 and 2. HIF-1alpha staining was performed as described previously [3]. In brief, antigen retrieval was performed in antigen retrieval solution (DAKO, Glostrup, Denmark) for 45 min at 96degreesC. The primary antibody against HIF-1alpha was incubated at a dilution of 1:500 for 30 min at room temperature and the catalyzed signal amplification system (DAKO) was used for detecting HIF-1alpha staining. Table 1Details of the immunohistochemical stainingsAntibodySpeciesCompany and institutesDilutionIncubationAntigen retrievalDetectionHIF-1alphaMouseBD Pharmingen1/50030' RTWB TRS 97degreesC 45'CSAAktRabbitCell Signaling1/50o/n 4degreesCWB Citr 97degreesC 10'ABCmTORRabbitCell Signaling1/50o/n 4degreesCWB Citr 97degreesC 10'ABCVHLMouseBD Pharmingen1/10060' RTWB Citr 97degreesC 20'PowervisionCA IXMouseLab Harris1/5030' RTnoneEnvision+Glut-1RabbitDAKO1/40060' RTWB Citr 97degreesC 20'ABCSDF-1MouseR&D systems1/400o/n 4degreesCWB Citr 97degreesC 10'ABCHydroxyprobe-1MouseChemicon International1/20040'RT0.01% pronase in PBS 40degreesC for 40'ABCBD Transduction laboratories, Mab monoclonal antibody, PAb polyclonal antibody, RT room temperature, WB water bath, TRS target retrieval solution (DAKO), Citr citrate buffer 10 mM pH 6.0, CSA catalyzed signal amplification system (DAKO), ABC avidin-biotinylated peroxidase complex, Powervision from immunologic R&D systemsTable 2Number (and percentages) of HIF-1alpha, P-AKT, P-mTOR, VHL, CA IX, GLUT1, and SDF-1 expression in nonprogressed and progressed colorectal adenomas and adenocarcinomas in the respective categories of staining intensity Nonprogressed Adenoma, n = 41Progressed adenoma, n = 20Adenocarcinoma, n = 23Kruskal-Wallis test, P-valueHIF-1Neg6 (15)2 (10)5 (22)0.8+0 (0)2 (10)1 (4)++7 (17)3 (15)3 (13)+++28 (68)13 (65)14 (61)AKTNeg0 (0)0 (0)0 (0)0.1+12 (29)7 (35)0 (0)++11 (27)5 (25)10 (43)+++18 (78)8 (40)13 (57)mTORNeg2 (5)0 (0)a0 (0)0.4+2 (5)3 (16)0 (0)++12 (29)6 (32)7 (30)+++25 (61)10 (53)16 (70)VHLNeg0 (0)a1 (5)0 (0)0.9+7 (18)0 (0)1 (4)++12 (30)11 (55)11 (48)+++21 (53)8 (40)11 (48)CA IXNeg10 (24)4 (20)1 (4)0.3+0 (0)0 (0)0 (0)++1 (2)2 (10)2 (9)+++30 (73)14 (70)20 (87)GLUT1Neg0 (0)1 (5)0 (0)0.02+8 (20)6 (30)0 (0)++15 (37)4 (20)6 (26)+++18 (44)9 (45)17 (74)SDF1Neg8 (20)a7 (37)a0 (0)<0.005+4 (10)4 (21)0 (0)++13 (33)2 (11)5 (22)+++15 (38)6 (32)18 (78)aOne case not tested
###end p 16
###begin p 17
Details of the immunohistochemical stainings
###end p 17
###begin p 18
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BD</italic>
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mab</italic>
###xml 55 58 55 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAb</italic>
###xml 80 82 80 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RT</italic>
###xml 101 103 101 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WB</italic>
###xml 116 119 116 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRS</italic>
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Citr</italic>
###xml 188 191 188 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSA</italic>
###xml 238 241 238 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABC</italic>
###xml 282 293 282 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Powervision</italic>
BD Transduction laboratories, Mab monoclonal antibody, PAb polyclonal antibody, RT room temperature, WB water bath, TRS target retrieval solution (DAKO), Citr citrate buffer 10 mM pH 6.0, CSA catalyzed signal amplification system (DAKO), ABC avidin-biotinylated peroxidase complex, Powervision from immunologic R&D systems
###end p 18
###begin p 19
Number (and percentages) of HIF-1alpha, P-AKT, P-mTOR, VHL, CA IX, GLUT1, and SDF-1 expression in nonprogressed and progressed colorectal adenomas and adenocarcinomas in the respective categories of staining intensity
###end p 19
###begin p 20
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aOne case not tested
###end p 20
###begin p 21
###xml 85 90 <span type="species:ncbi:10090">mouse</span>
###xml 218 229 <span type="species:ncbi:3704">horseradish</span>
###xml 252 257 <span type="species:ncbi:10090">mouse</span>
For CA IX staining, no antigen retrieval step was used. Slides were incubated with a mouse primary antibody to CA IX in a 1:50 dilution for 30 min at room temperature. Detection was performed with the Envision+ system-horseradish peroxidase system for mouse primary antibodies (DAKO).
###end p 21
###begin p 22
###xml 37 43 <span type="species:ncbi:9986">rabbit</span>
GLUT-1 staining was performed with a rabbit polyclonal anti-GLUT1 (antibody clone A 3536, DAKO, dilution 1:400) without antigen retrieval and subsequently developed with a standard avidin-biotinylated peroxidase complex (DAKO).
###end p 22
###begin p 23
Staining procedures for AKT and mTOR were identical. After antigen retrieval, endogenous peroxidase activity was blocked for 10 min in methanol containing 0.3% hydrogen peroxide. The AKT antibody (Phospho-Akt (Ser473)) and mTOR antibody (Phospho-mTOR (Ser2448)) both obtained from Cell Signaling (Danvers, MA, USA) were incubated overnight at 4degreesC in a 1:50 dilution and subsequently detected with a standard avidin-biotinylated peroxidase complex.
###end p 23
###begin p 24
###xml 114 118 <span type="species:ncbi:9925">goat</span>
###xml 124 130 <span type="species:ncbi:9986">rabbit</span>
SDF-1 staining was performed similar to the AKT and mTOR staining, except for the secondary antibody, which was a goat anti-rabbit antibody in this case.
###end p 24
###begin p 25
For VHL staining, antigen retrieval was performed and endogenous peroxidase was blocked as the AKT and mTOR staining. Primary antibody against VHL was incubated for 60 min by room temperature, followed by Powervision (Immunologic, Duiven, the Netherlands) incubation for 30 min and subsequently the staining was detected with diaminobenzidine (SIGMA FASTtrade mark 3,3'-diaminobenzidine tablets, Sigma Aldrich, St. Louis, MO, USA).
###end p 25
###begin p 26
Before the slides were mounted with cover slips, all sections were counterstained for 30 s with Mayer's hematoxylin and dehydrated in 70%, 96%, and subsequently 100% ethanol and finally in xylene.
###end p 26
###begin title 27
Evaluation and statistics
###end title 27
###begin p 28
###xml 659 660 655 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The intensity of the staining was compared between the normal mucosa, nonprogressed, progressed adenomas, and carcinomas and scored by two investigators. Staining intensity was scored in four classes (0 to 3) taking the negative control as a reference for score 0 and the positive control (clear cell renal adenocarcinomas (Grawitz tumor) as a reference for score 3). For HIF-1alpha, only nuclear staining was scored, for CA IX, membrane staining, and AKT and SDF-1 cytoplasmic staining, for mTOR predominantly cytoplasmic but also membrane staining was scored. Significance of differences between categories was analyzed by means of the Kruskal Wallis test. P-values < 0.05 were considered to be significant.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
HIF-1alpha expression and its regulators hypoxia and VHL
###end title 30
###begin p 31
###xml 120 121 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 489 490 481 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 663 669 651 657 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 669 1105 657 1081 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">Serial sections of normal colon mucosa, colorectal adenoma, and adenocarcinoma analyzed for HIF-1&#945; and VHL expression. HIF-1&#945; staining was observed in the nuclei of surface epithelium of normal mucosa and colorectal adenoma, whereas in adenocarcinomas HIF-1&#945; was present near hypoxic regions with necrosis. VHL expression was observed in the cytoplasma of all epithelial cells of normal mucosa, adenomas, and adenocarcinomas</p>
###xml 669 1105 657 1081 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32">Serial sections of normal colon mucosa, colorectal adenoma, and adenocarcinoma analyzed for HIF-1&#945; and VHL expression. HIF-1&#945; staining was observed in the nuclei of surface epithelium of normal mucosa and colorectal adenoma, whereas in adenocarcinomas HIF-1&#945; was present near hypoxic regions with necrosis. VHL expression was observed in the cytoplasma of all epithelial cells of normal mucosa, adenomas, and adenocarcinomas</p></caption>
###xml 1105 1105 1081 1081 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="428_2008_578_Fig2_HTML" id="MO2"/>
###xml 663 1105 651 1081 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="32">Serial sections of normal colon mucosa, colorectal adenoma, and adenocarcinoma analyzed for HIF-1&#945; and VHL expression. HIF-1&#945; staining was observed in the nuclei of surface epithelium of normal mucosa and colorectal adenoma, whereas in adenocarcinomas HIF-1&#945; was present near hypoxic regions with necrosis. VHL expression was observed in the cytoplasma of all epithelial cells of normal mucosa, adenomas, and adenocarcinomas</p></caption><graphic position="anchor" xlink:href="428_2008_578_Fig2_HTML" id="MO2"/></fig>
###xml 1105 1111 1081 1087 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 1177 1178 1153 1154 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1222 1223 1198 1199 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1111 1505 1087 1481 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">Detection of hypoxia in murine colorectal mucosa by pimonidazole. <bold>a</bold> Colorectal mucosa of a non-injected mouse, <bold>b</bold> colorectal mucosa of a mouse that was injected intravenously with pimonidazole. After 90&#160;min, the mouse was killed and colon tissue harvested and formalin fixed. Immunohistochemical staining against pimonidazole revealed hypoxia in the surface epithelium of the normal colon mucosa</p>
###xml 1111 1505 1087 1481 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">Detection of hypoxia in murine colorectal mucosa by pimonidazole. <bold>a</bold> Colorectal mucosa of a non-injected mouse, <bold>b</bold> colorectal mucosa of a mouse that was injected intravenously with pimonidazole. After 90&#160;min, the mouse was killed and colon tissue harvested and formalin fixed. Immunohistochemical staining against pimonidazole revealed hypoxia in the surface epithelium of the normal colon mucosa</p></caption>
###xml 1505 1505 1481 1481 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="428_2008_578_Fig3_HTML" id="MO3"/>
###xml 1105 1505 1081 1481 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="33">Detection of hypoxia in murine colorectal mucosa by pimonidazole. <bold>a</bold> Colorectal mucosa of a non-injected mouse, <bold>b</bold> colorectal mucosa of a mouse that was injected intravenously with pimonidazole. After 90&#160;min, the mouse was killed and colon tissue harvested and formalin fixed. Immunohistochemical staining against pimonidazole revealed hypoxia in the surface epithelium of the normal colon mucosa</p></caption><graphic position="anchor" xlink:href="428_2008_578_Fig3_HTML" id="MO3"/></fig>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 478 482 <span type="species:ncbi:10090">mice</span>
###xml 557 561 <span type="species:ncbi:10090">mice</span>
###xml 638 643 <span type="species:ncbi:9606">human</span>
###xml 1135 1141 <span type="species:ncbi:10090">murine</span>
###xml 1215 1220 <span type="species:ncbi:10090">mouse</span>
###xml 1247 1252 <span type="species:ncbi:10090">mouse</span>
###xml 1322 1327 <span type="species:ncbi:10090">mouse</span>
In normal colorectal mucosa nine out of ten samples showed HIF-1alpha present in nuclei of the surface epithelium (Fig. 2). To evaluate whether hypoxia played a physiologic role in the induction of HIF-1alpha in normal colorectal mucosa, we used mice that were injected with pimonidazole, a chemical marker of hypoxia that can be visualized by immunohistochemistry. The presence of tissue hypoxia was demonstrated in the surface epithelium of normal colon mucosa of the treated mice (Fig. 3). The pattern of hypoxic cells in the normal colorectal mucosa in mice matched with the distribution of HIF-1alpha immunohistochemical staining in human colorectal mucosa. Fig. 2Serial sections of normal colon mucosa, colorectal adenoma, and adenocarcinoma analyzed for HIF-1alpha and VHL expression. HIF-1alpha staining was observed in the nuclei of surface epithelium of normal mucosa and colorectal adenoma, whereas in adenocarcinomas HIF-1alpha was present near hypoxic regions with necrosis. VHL expression was observed in the cytoplasma of all epithelial cells of normal mucosa, adenomas, and adenocarcinomasFig. 3Detection of hypoxia in murine colorectal mucosa by pimonidazole. a Colorectal mucosa of a non-injected mouse, b colorectal mucosa of a mouse that was injected intravenously with pimonidazole. After 90 min, the mouse was killed and colon tissue harvested and formalin fixed. Immunohistochemical staining against pimonidazole revealed hypoxia in the surface epithelium of the normal colon mucosa
###end p 31
###begin p 32
Serial sections of normal colon mucosa, colorectal adenoma, and adenocarcinoma analyzed for HIF-1alpha and VHL expression. HIF-1alpha staining was observed in the nuclei of surface epithelium of normal mucosa and colorectal adenoma, whereas in adenocarcinomas HIF-1alpha was present near hypoxic regions with necrosis. VHL expression was observed in the cytoplasma of all epithelial cells of normal mucosa, adenomas, and adenocarcinomas
###end p 32
###begin p 33
###xml 66 67 66 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 111 112 111 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 24 30 <span type="species:ncbi:10090">murine</span>
###xml 104 109 <span type="species:ncbi:10090">mouse</span>
###xml 136 141 <span type="species:ncbi:10090">mouse</span>
###xml 211 216 <span type="species:ncbi:10090">mouse</span>
Detection of hypoxia in murine colorectal mucosa by pimonidazole. a Colorectal mucosa of a non-injected mouse, b colorectal mucosa of a mouse that was injected intravenously with pimonidazole. After 90 min, the mouse was killed and colon tissue harvested and formalin fixed. Immunohistochemical staining against pimonidazole revealed hypoxia in the surface epithelium of the normal colon mucosa
###end p 33
###begin p 34
###xml 375 376 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 402 403 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
The presence of HIF-1alpha in normal colorectal mucosa was compared with that in adenomas and carcinomas. Adenomas displayed HIF-1alpha expression in 53 of the 61 cases, predominantly at the surface, gradually decreasing towards the center of the adenomas. No differences were seen between nonprogressed and progressed adenomas (85% and 90%, respectively), as shown in Table 2. Of the carcinomas, 78% (n = 18) were positive, showing nuclear staining of HIF-1alpha in epithelial tumor cells. In carcinomas, a decreasing gradient of HIF-1alpha staining was observed from necrotic areas towards the well-vascularized stroma. Besides the epithelial tumor cells, in carcinomas, inflammatory cells in the tumor-associated stroma, and in five cases B-cells in lymph follicles, were positive for HIF-1alpha. Statistical analysis showed no significant differences in intensity of HIF-1alpha staining between normal mucosa, adenomas, and carcinomas.
###end p 34
###begin p 35
###xml 103 104 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
VHL, the regulator of HIF-1alpha degradation, was also analyzed by means of immunohistochemistry (Fig. 2). VHL expression was observed in all epithelial cells in normal colorectal mucosa as well as in colorectal adenomas and carcinomas.
###end p 35
###begin title 36
AKT and mTOR, oncogenic pathways regulating HIF-1alpha
###end title 36
###begin p 37
###xml 412 413 404 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 781 787 773 779 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 861 862 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 863 866 855 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AKT</italic>
###xml 878 879 870 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 880 884 872 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mTOR</italic>
###xml 787 1397 779 1389 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38">Typical immunohistochemical staining patterns of the active forms of AKT (<italic>P</italic>-<italic>AKT</italic>) and mTOR (<italic>P</italic>-<italic>mTOR</italic>) in normal colon mucosa, colorectal adenoma, and adenocarcinomas. Presence of active AKT is seen in the cytoplasm of all epithelial cells with increasing intensities from the normal mucosa towards adenocarcinoma. Presence of active mTOR is restricted to the surface epithelium in normal mucosa and adenomas. In adenocarcinomas, cells surrounding necrotic areas show active mTOR as well. In addition, in adenocarcinomas, intracellular localization of mTOR changes from cytoplasm towards cellular membrane staining</p>
###xml 787 1397 779 1389 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="38">Typical immunohistochemical staining patterns of the active forms of AKT (<italic>P</italic>-<italic>AKT</italic>) and mTOR (<italic>P</italic>-<italic>mTOR</italic>) in normal colon mucosa, colorectal adenoma, and adenocarcinomas. Presence of active AKT is seen in the cytoplasm of all epithelial cells with increasing intensities from the normal mucosa towards adenocarcinoma. Presence of active mTOR is restricted to the surface epithelium in normal mucosa and adenomas. In adenocarcinomas, cells surrounding necrotic areas show active mTOR as well. In addition, in adenocarcinomas, intracellular localization of mTOR changes from cytoplasm towards cellular membrane staining</p></caption>
###xml 1397 1397 1389 1389 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="428_2008_578_Fig4_HTML" id="MO4"/>
###xml 781 1397 773 1389 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="38">Typical immunohistochemical staining patterns of the active forms of AKT (<italic>P</italic>-<italic>AKT</italic>) and mTOR (<italic>P</italic>-<italic>mTOR</italic>) in normal colon mucosa, colorectal adenoma, and adenocarcinomas. Presence of active AKT is seen in the cytoplasm of all epithelial cells with increasing intensities from the normal mucosa towards adenocarcinoma. Presence of active mTOR is restricted to the surface epithelium in normal mucosa and adenomas. In adenocarcinomas, cells surrounding necrotic areas show active mTOR as well. In addition, in adenocarcinomas, intracellular localization of mTOR changes from cytoplasm towards cellular membrane staining</p></caption><graphic position="anchor" xlink:href="428_2008_578_Fig4_HTML" id="MO4"/></fig>
To investigate whether, in addition to hypoxia, oncogenes and/or growth factors can contribute to the elevated HIF-1alpha, we studied the presence of phosphorylated forms of AKT and mTOR, which reflect an active state of the oncogene-driven pathway of HIF-1alpha activation. Low-intensity cytoplasmic staining for the active form of AKT (P-AKT) was seen in epithelial cells of normal mucosa in all tissues (Fig. 4). Positive staining was also seen in the smooth muscle cells of the muscularis propria and muscularis mucosae and in the walls of blood vessels. In adenomas, staining in epithelial cells was more intense, present throughout the neoplastic tissue, and observed in all cases. Staining patterns in adenocarcinomas were similar and also observed in all samples analyzed. Fig. 4Typical immunohistochemical staining patterns of the active forms of AKT (P-AKT) and mTOR (P-mTOR) in normal colon mucosa, colorectal adenoma, and adenocarcinomas. Presence of active AKT is seen in the cytoplasm of all epithelial cells with increasing intensities from the normal mucosa towards adenocarcinoma. Presence of active mTOR is restricted to the surface epithelium in normal mucosa and adenomas. In adenocarcinomas, cells surrounding necrotic areas show active mTOR as well. In addition, in adenocarcinomas, intracellular localization of mTOR changes from cytoplasm towards cellular membrane staining
###end p 37
###begin p 38
###xml 74 75 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 76 79 76 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AKT</italic>
###xml 91 92 91 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mTOR</italic>
Typical immunohistochemical staining patterns of the active forms of AKT (P-AKT) and mTOR (P-mTOR) in normal colon mucosa, colorectal adenoma, and adenocarcinomas. Presence of active AKT is seen in the cytoplasm of all epithelial cells with increasing intensities from the normal mucosa towards adenocarcinoma. Presence of active mTOR is restricted to the surface epithelium in normal mucosa and adenomas. In adenocarcinomas, cells surrounding necrotic areas show active mTOR as well. In addition, in adenocarcinomas, intracellular localization of mTOR changes from cytoplasm towards cellular membrane staining
###end p 38
###begin p 39
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 827 828 827 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
Active mTOR was only present as a cytoplasmatic staining; nuclear staining was not observed in any of the cases (Fig. 4). In normal mucosa, mTOR was detected in the surface epithelium in all tissues. Likewise, in adenoma samples, mTOR was expressed in the surface epithelium but also more diffusely throughout the adenomas. In adenocarcinomas, staining patterns were diffused across the whole tumor, but more intense expression was detected in areas surrounding necrosis. Higher levels of active mTOR were observed at the invasive front of the tumor. In the adenocarcinomas, besides the cytoplasmic staining in some cells, a clear cellular membrane staining was observed. In all normal mucosa samples, adenomas, and carcinomas, mTOR was present, except for 5% of the nonprogressed adenomas, which were negative for mTOR (Table 2).
###end p 39
###begin title 40
Expression of the HIF1 downstream targets Glut1 and SDF-1
###end title 40
###begin p 41
###xml 462 463 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 641 642 637 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 800 801 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 1031 1032 1027 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1035 1041 1031 1037 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 1041 1567 1037 1551 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">Typical immunohistochemical staining patterns of HIF-1&#945;, GLUT1, SDF-1, and CA IX in normal colon mucosa, colorectal adenomas, and adenocarcinomas. The downstream targets of HIF-1, i.e., SDF-1, GLUT1, and CA IX, have predominantly overlapping staining with the presence of HIF-1. However, in normal mucosa, CA IX is not expressed in the HIF-1&#945; positive surface epithelium but is expressed in the basal of the crypts. In adenocarcinomas, SDF-1 is not only present in HIF-1&#945;-positive cells but in all epithelial cells</p>
###xml 1041 1567 1037 1551 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42">Typical immunohistochemical staining patterns of HIF-1&#945;, GLUT1, SDF-1, and CA IX in normal colon mucosa, colorectal adenomas, and adenocarcinomas. The downstream targets of HIF-1, i.e., SDF-1, GLUT1, and CA IX, have predominantly overlapping staining with the presence of HIF-1. However, in normal mucosa, CA IX is not expressed in the HIF-1&#945; positive surface epithelium but is expressed in the basal of the crypts. In adenocarcinomas, SDF-1 is not only present in HIF-1&#945;-positive cells but in all epithelial cells</p></caption>
###xml 1567 1567 1551 1551 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="428_2008_578_Fig5_HTML" id="MO5"/>
###xml 1035 1567 1031 1551 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="42">Typical immunohistochemical staining patterns of HIF-1&#945;, GLUT1, SDF-1, and CA IX in normal colon mucosa, colorectal adenomas, and adenocarcinomas. The downstream targets of HIF-1, i.e., SDF-1, GLUT1, and CA IX, have predominantly overlapping staining with the presence of HIF-1. However, in normal mucosa, CA IX is not expressed in the HIF-1&#945; positive surface epithelium but is expressed in the basal of the crypts. In adenocarcinomas, SDF-1 is not only present in HIF-1&#945;-positive cells but in all epithelial cells</p></caption><graphic position="anchor" xlink:href="428_2008_578_Fig5_HTML" id="MO5"/></fig>
To investigate to what extent downstream pathways were affected by HIF-1 upregulation, several HIF-1 target genes, including GLUT1 and SDF-1, were analyzed in normal mucosa, adenomas, and adenocarcinomas. Expression of GLUT1, which is involved in glucose metabolism, was closely correlated with HIF-1alpha in all colon tissues analyzed. In normal colon mucosa, GLUT1 expression showed a gradient from the surface epithelium towards the basis of the crypts (Fig. 5). All normal tissues showed a positive GLUT1 staining. In nonprogressed adenomas, all cases showed GLUT1 expression compared to 95% of progressed adenomas. All adenocarcinomas (n = 23) were positive for GLUT1 as well. Staining was localized at the cell membrane of epithelial cells in normal mucosa, adenomas, and adenocarcinomas (Fig. 5). Most intense staining was seen at the surface epithelium of adenomas and in the vicinity of necrosis in carcinomas. As to staining intensity, a significant difference was detected between the adenomas and the carcinomas (Table 2). Fig. 5Typical immunohistochemical staining patterns of HIF-1alpha, GLUT1, SDF-1, and CA IX in normal colon mucosa, colorectal adenomas, and adenocarcinomas. The downstream targets of HIF-1, i.e., SDF-1, GLUT1, and CA IX, have predominantly overlapping staining with the presence of HIF-1. However, in normal mucosa, CA IX is not expressed in the HIF-1alpha positive surface epithelium but is expressed in the basal of the crypts. In adenocarcinomas, SDF-1 is not only present in HIF-1alpha-positive cells but in all epithelial cells
###end p 41
###begin p 42
Typical immunohistochemical staining patterns of HIF-1alpha, GLUT1, SDF-1, and CA IX in normal colon mucosa, colorectal adenomas, and adenocarcinomas. The downstream targets of HIF-1, i.e., SDF-1, GLUT1, and CA IX, have predominantly overlapping staining with the presence of HIF-1. However, in normal mucosa, CA IX is not expressed in the HIF-1alpha positive surface epithelium but is expressed in the basal of the crypts. In adenocarcinomas, SDF-1 is not only present in HIF-1alpha-positive cells but in all epithelial cells
###end p 42
###begin p 43
###xml 355 356 351 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 680 681 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 803 804 791 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 807 813 795 801 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;6</label>
###xml 813 908 801 896 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44">SDF-1 expression in epithelial and endothelial cells of normal detected by immunohistochemistry</p>
###xml 813 908 801 896 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44">SDF-1 expression in epithelial and endothelial cells of normal detected by immunohistochemistry</p></caption>
###xml 908 908 896 896 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="428_2008_578_Fig6_HTML" id="MO6"/>
###xml 807 908 795 896 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>Fig.&#160;6</label><caption><p textid="44">SDF-1 expression in epithelial and endothelial cells of normal detected by immunohistochemistry</p></caption><graphic position="anchor" xlink:href="428_2008_578_Fig6_HTML" id="MO6"/></fig>
In normal colon tissue, SDF-1 expression was comparable to that of HIF-1alpha, i.e., it was detected in a gradient from the surface epithelium towards the basis of the crypts. However, in all colorectal adenomas and adenocarcinomas, intense SDF-1 expression was observed in the epithelial cells, which was located in the cell membrane and cytoplasm (Fig. 5). Because this epithelial SDF-1 expression was seen in all epithelial cells, it co-localized only partly with HIF-1alpha presence. In contrast to the comparable intensity of the HIF-1alpha staining in adenomas and adenocarcinomas, the SDF-1 staining intensity was much higher in adenocarcinomas than in the adenomas (Table 2). In addition to the epithelial expression of SDF-1, endothelial cells of blood vessels stained positive for SDF-1 (Fig. 6). Fig. 6SDF-1 expression in epithelial and endothelial cells of normal detected by immunohistochemistry
###end p 43
###begin p 44
SDF-1 expression in epithelial and endothelial cells of normal detected by immunohistochemistry
###end p 44
###begin title 45
Expression of CA IX
###end title 45
###begin p 46
###xml 664 665 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
CA IX was originally identified in gastrointestinal tissues and later recognized as a HIF-1 target gene in many tissues. In normal mucosa, the presence of CA IX actually did not co-localize with that of HIF-1alpha. CA IX was observed in the bottom parts of the crypts, i.e., in the proliferative compartment, in contrast to HIF-1alpha, which was present in the surface epithelium. Seventy percent of the normal tissues showed CA IX expression. In adenomas and particular adenocarcinomas, CA IX and HIF-1 expressions had more resemblance. In adenomas, CA IX was present in a more diffuse pattern throughout the whole adenoma, including the surface epithelium (Fig. 5). In the adenocarcinomas, CA IX showed a peri-necrotic staining, mainly co-localizing with the HIF-1alpha expression.
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 615 621 <span type="species:ncbi:10090">murine</span>
The present study demonstrates the presence of nuclear HIF-1alpha in the surface epithelium of normal colon and adenomas and in areas associated with peri-necrotic areas of colon adenocarcinoma. The data support a hypoxia-induced HIF-1 cascade, both in normal and neoplastic colorectal mucosa, as suggested by pimonidazole and HIF-1alpha patterns in association with GLUT1 and SDF-1 in normal colorectal mucosa and adenomas, as well as peri-necrotic HIF-1alpha and CA IX patterns in colorectal carcinomas. The occurrence of hypoxia around the surface epithelium was confirmed by pimonidazole staining of unaffected murine colon. Furthermore, hypoxia and the oncogenic activation of the AKT-mTOR pathway both contributed to HIF-1 expression in adenomas and adenocarcinomas. Moreover, the expression patterns of CA IX in normal mucosa and SDF-1 in neoplastic mucosa pointed to additional regulations independent from HIF-1.
###end p 48
###begin title 49
The hypoxia-HIF-1 cascade
###end title 49
###begin p 50
###xml 446 448 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
The presence of HIF-1alpha under physiological circumstances in the surface epithelium of normal colorectal mucosa observed in the present study may be due to the anaerobic environment in the lumen of the colon, which contributes to a relatively hypoxic state of especially this surface epithelium. Indeed, we observed accumulation of the chemical hypoxia marker pimonidazole particularly in the surface epithelium, indicating low oxygen levels [19]. The presence of pimonidazole showed a gradient towards the basis of the crypts, suggesting that the cause of hypoxia was indeed related to the anaerobic lumen. Apparently, the capillaries in the surface regions of the colon epithelium were unable to cope with the high oxygen demand of the tissue. This strongly suggests that these hypoxic areas may induce HIF-1alpha, which contributes to a sustained pressure on the stimulation of angiogenesis and glycolysis to adjust the energy levels of these cells.
###end p 50
###begin p 51
###xml 41 48 <span type="species:ncbi:9606">patient</span>
Although immunohistochemical analysis of patient samples does not allow a formal analysis of functional relationships, it is highly likely that the HIF-1 detected in normal colorectal mucosa was transcriptionally active because HIF-1alpha was detected in the nuclei and the HIF-1 downstream targets GLUT1 and SDF-1 were present in the same regions where HIF-1alpha was found.
###end p 51
###begin p 52
In 87% of colorectal adenomas, HIF-1alpha was present, showing staining predominantly in the nuclei of the surface epithelium. In colorectal adenocarcinomas, the presence of HIF-1alpha changes from the surface epithelium to epithelium cells surrounding regions of necrosis, indicating severe hypoxia. Presence of HIF-1alpha in the nuclei of epithelial cells went along with expression of the downstream targets GLUT1 and SDF1 in all different stages of the colon carcinogenesis.
###end p 52
###begin p 53
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 623 625 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 849 851 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 853 855 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
In contrast to SDF-1 and GLUT1, the downstream target CA IX, known as a stringent hypoxia marker [35], did not co-localize with HIF-1alpha staining in normal colorectal mucosa. It should be noted that CA IX was originally described to have a role in maintaining the physiological equilibrium in the gastrointestinal tract. In fact, CA IX was more abundant in the basal half of the crypts, containing the proliferating compartment, rather than in the upper half of the mucosa where HIF-1alpha expression was observed. Indeed, co-localization of CA IX with Ki-67, a proliferation marker, has been found in colorectal cancer [31]. The lack of HIF-1alpha in the CA IX-positive regions indicates an HIF-1alpha-independent regulation of CA IX in normal colon epithelium. CA IX expression was reported to be also regulated by the transcription factor SP1 [18, 31].
###end p 53
###begin title 54
Oncogenic upregulation of HIF-1
###end title 54
###begin p 55
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 84 86 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 736 738 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1313 1315 1285 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
Oncogene-dependent regulation of HIF-1 can be mediated by the AKT-mTOR pathway [24, 39]. In the present study, in epithelium of all normal colorectal mucosa, a weak staining of P-AKT was observed, confirming data of Itoh et al. [14]. In all adenomas and adenocarcinomas analyzed, the active (phosphorylated) forms of AKT and mTOR were detected as well. Especially active mTOR showed co-localization with HIF-1alpha in normal tissue as well as in adenomas and adenocarcinomas. Co-localization of P-AKT with HIF-1alpha was less evident. Recently, in breast cancer, it has been shown that in the absence of P-AKT, only low levels of HIF-1alpha could be detected while in the presence of P-AKT high HIF-1alpha protein levels were observed [10]. In colorectal tumorigenesis, this regulation mechanism may be less relevant because staining was already observed in normal tissue. In addition, the presence of active AKT was not HIF-1 related because in adenocarcinomas P-AKT was present in a higher percentage of cells present than HIF-1alpha. The downstream target of AKT, mTOR, displayed comparable cellular expression patterns to HIF-1alpha in normal, adenomas, and carcinomas. This suggests that the AKT-mTOR-HIF-1alpha axis may be important in tumor growth and development as was seen in prostate epithelial cells [25].
###end p 55
###begin title 56
Expression of VHL
###end title 56
###begin p 57
###xml 222 223 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 225 227 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 358 360 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 430 432 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 420 428 <span type="species:ncbi:9606">patients</span>
An alternative mechanism that can lead to HIF-1alpha overexpression is loss of VHL expression. In normal colon mucosa, VHL is expressed, while in colorectal tumors VHL has been found to be lost or mutated in 11% of cases [7, 21]. Mutations in the VHL gene have been reported to result in cytoplasmic staining of HIF-1alpha in colorectal cancer in one study [22], while this could not be confirmed in another study of 80 patients [40]. Also in the present study, no cytoplasmic staining of HIF-1 alpha was seen at all, and VHL expression was seen in all epithelial cells of normal mucosa, colorectal adenomas, and carcinoma.
###end p 57
###begin title 58
Expression of SDF1
###end title 58
###begin p 59
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 433 435 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 527 529 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 695 697 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 813 815 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
SDF-1 was investigated in the present study as a downstream target of HIF-1 [13, 32]. Surprisingly, epithelial cells showed much stronger SDF-1 expression than endothelial cells lining blood vessels. In addition, expression was not merely restricted to areas showing HIF-1alpha staining but was observed in all epithelial adenomas and adenocarcinomas. SDF-1 staining in tumors cells has also been reported in breast cancer patients [29] and in clear cell-renal cell carcinomas, in which HIF-1alpha is constitutively expressed [37]. The intense staining of the colon tumor cells suggests that SDF-1 not only has a function in attracting circulating progenitor cells towards the angiogenic areas [12]. Indeed, SDF-1 stimulates intestinal epithelial cell migration and enhances the integrity of the mucosal barrier [34].
###end p 59
###begin p 60
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
The level of expression of SDF-1 might also play a role in tumorigenesis because it is related with prognosis in colorectal cancer. The presence of its coding mRNA and the mRNA of its receptor, CXCR4, have been shown to be a poor prognostic factor [20]. In tumor formation, SDF-1 may bear impact on the recruitment of various types of progenitor cells needed for enhanced growth of the tumor tissue [29]. Our study supports a role of SDF-1 in carcinogenesis because SDF-1 staining becomes more intense with the progression of normal colon tissue toward carcinomas. However, future studies are needed to substantiate such role.
###end p 60
###begin title 61
Conclusion
###end title 61
###begin p 62
The common expression of HIF-1alpha in the surface epithelium of the colorectal mucosa suggests that HIF-1 may play a role in the physiology of normal colon tissue. HIF-1alpha presence does not appear to be related to progression of colorectal carcinogenesis in contrast to GLUT1 and SDF-1, which are expressed more intensely at later stages of this process.
###end p 62
###begin title 63
Acknowledgements
###end title 63
###begin p 64
The authors thank Cristel Snijckers and Helma van den Berg for technical assistance and Prof. A.L. Harris for providing the CA IX antibody. This work was supported in part by the 1st AEGON International Scholarship in Oncology.
###end p 64
###begin p 65
###xml 0 30 0 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Conflict of interest statement</bold>
Conflict of interest statement We declare that we have no conflict of interest.
###end p 65
###begin p 66
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 66
###begin title 67
References
###end title 67
###begin article-title 68
GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding
###end article-title 68
###begin article-title 69
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/- compound mutant mice
###end article-title 69
###begin article-title 70
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis
###end article-title 70
###begin article-title 71
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Levels of hypoxia-inducible factor-1 alpha independently predict prognosis in patients with lymph node negative breast carcinoma
###end article-title 71
###begin article-title 72
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
###end article-title 72
###begin article-title 73
Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas
###end article-title 73
###begin article-title 74
Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis
###end article-title 74
###begin article-title 75
Regulation of translation initiation by FRAP/mTOR
###end article-title 75
###begin article-title 76
###xml 11 16 <span type="species:ncbi:9606">human</span>
Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers
###end article-title 76
###begin article-title 77
Hypoxia-inducible factor-1alpha expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas
###end article-title 77
###begin article-title 78
Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1)
###end article-title 78
###begin article-title 79
VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells
###end article-title 79
###begin article-title 80
###xml 76 81 <span type="species:ncbi:9606">human</span>
Mucosal angiogenesis regulation by CXCR4 and its ligand CXCL12 expressed by human intestinal microvascular endothelial cells
###end article-title 80
###begin article-title 81
###xml 105 110 <span type="species:ncbi:9606">human</span>
Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma
###end article-title 81
###begin article-title 82
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing
###end article-title 82
###begin article-title 83
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation
###end article-title 83
###begin article-title 84
Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer
###end article-title 84
###begin article-title 85
Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia- responsive enhancer
###end article-title 85
###begin article-title 86
###xml 55 61 <span type="species:ncbi:10090">murine</span>
Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis
###end article-title 86
###begin article-title 87
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival
###end article-title 87
###begin article-title 88
###xml 90 95 <span type="species:ncbi:9606">human</span>
Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma
###end article-title 88
###begin article-title 89
###xml 48 53 <span type="species:ncbi:9606">human</span>
Mutation of the von Hippel-Lindau (VHL) gene in human colorectal carcinoma: association with cytoplasmic accumulation of hypoxia-inducible factor (HIF)-1alpha
###end article-title 89
###begin article-title 90
###xml 39 44 <span type="species:ncbi:9606">human</span>
Transcriptional response to hypoxia in human tumors
###end article-title 90
###begin article-title 91
Her2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (hif-1alpha) synthesis: novel mechanism for hif-1-mediated vascular endothelial growth factor expression
###end article-title 91
###begin article-title 92
Akt-regulated pathways in prostate cancer
###end article-title 92
###begin article-title 93
Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1
###end article-title 93
###begin article-title 94
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
###end article-title 94
###begin article-title 95
Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer
###end article-title 95
###begin article-title 96
###xml 40 45 <span type="species:ncbi:9606">human</span>
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion
###end article-title 96
###begin article-title 97
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis
###end article-title 97
###begin article-title 98
Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation
###end article-title 98
###begin article-title 99
CXCR4/CXCL12 expression and signalling in kidney cancer
###end article-title 99
###begin article-title 100
Targeting HIF-1 for cancer therapy
###end article-title 100
###begin article-title 101
CXCL12 activation of CXCR4 regulates mucosal host defense through stimulation of epithelial cell migration and promotion of intestinal barrier integrity
###end article-title 101
###begin article-title 102
Hypoxia-inducible expression of tumor-associated carbonic anhydrases
###end article-title 102
###begin article-title 103
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression
###end article-title 103
###begin article-title 104
Stromal cell-derived factor-1 alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor
###end article-title 104
###begin article-title 105
###xml 60 65 <span type="species:ncbi:9606">human</span>
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases
###end article-title 105
###begin article-title 106
###xml 143 148 <span type="species:ncbi:9606">human</span>
Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics
###end article-title 106
###begin article-title 107
###xml 76 81 <span type="species:ncbi:9606">human</span>
von Hippel-Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens
###end article-title 107
###begin p 108
Part of this work was financially supported by the 1st AEGON International Scholarship in Oncology (AEG, PMDvD, RJAF).
###end p 108

